De-chao Yu

发表

Advances in Brief Antitumor Synergy of CV 787 , a Prostate Cancer-specific Adenovirus , and Paclitaxel and Docetaxel

M. Embry, Hong Zhang, J. Oh, 2001 .

Antitumor Efficacy without Increasing Toxicity Combination with Radiotherapy Produces Synergistic CV 706 , a Prostate Cancer-specific Adenovirus Variant , in Updated Version

T. DeWeese, D. Karpf, Ja-Kyeong Lee, 2001 .

SARI attenuates colon inflammation by promoting STAT1 degradation in intestinal epithelial cells

Yuquan Wei, Zongguang Zhou, P. Fan, 2019, Mucosal Immunology.

Development of novel E1-complementary cells for adenoviral production free of replication-competent adenovirus.

K. Segawa, T. Harding, D. Mittelstaedt, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy.

P. Working, J. Dilley, Yuanhao Li, 2003, Molecular cancer therapeutics.

Development of Attenuated Replication Competent Adenoviruses (ARCAs) for the Treatment of Prostate Cancer

D. R. Henderson, De-Chao Yu, D. Henderson, 2002 .

Development of transcriptionally regulated oncolytic adenoviruses

L. Hawkins, D. Ko, De-chao Yu, 2005, Oncogene.

Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel.

P. Working, N. Ramesh, J. Dilley, 2002, Cancer research.

CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor–Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer

D. Ennist, Y. Ge, S. Ganesh, 2006, Clinical Cancer Research.

Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity

P. Working, De-Chao Yu, J. Dilley, 2005, Cancer Gene Therapy.

Selectively replicating oncolytic adenoviruses as cancer therapeutics.

P. Working, D. Ando, De-chao Yu, 2002, Current opinion in molecular therapeutics.

Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma.

Ping Chen, L. Teng, Jiang Cao, 2009, Hepatobiliary & pancreatic diseases international : HBPD INT.

Dual Promoter–Controlled Oncolytic Adenovirus CG5757 Has Strong Tumor Selectivity and Significant Antitumor Efficacy in Preclinical Models

S. Thorne, P. Working, T. Reid, 2005, Clinical Cancer Research.

Potent and long‐term antiangiogenic efficacy mediated by FP3‐expressing oncolytic adenovirus

C. Yun, J. Yoo, June Kyu Hwang, 2015, International journal of cancer.

Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium.

Y. Ge, N. Ramesh, M. Vanroey, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects.

Yuquan Wei, C. Yun, H. Deng, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Complex mosaicism is a novel approach to infectivity enhancement of adenovirus type 5-based vectors

D. Curiel, N. Ramesh, A. Borovjagin, 2005, Cancer Gene Therapy.

Enhanced Gene Transfer and Oncolysis of Head and Neck Cancer and Melanoma Cells by Fiber Chimeric Oncolytic Adenoviruses

S. Ganesh, P. Reddy, De-chao Yu, 2006, Clinical Cancer Research.

CG0070, a conditionally replicating GM-CSF armed oncolytic adenovirus for the treatment of bladder cancer

Y. Ge, N. Ramesh, De-chao Yu, 2005 .

A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration.

P. Kaiser, Wenjing Zhu, M. Yan, 2011, Ophthalmology.

Adenovirus for Prostate Cancer Therapy Calydon Virus 764, an Attenuated Replication Competent Human Kallikrein 2 and Their Use in the Construction of Identification of the Transcriptional Regulatory Sequences

D. R. Henderson, G. T. Sakamoto, D. Henderson, 1999 .

A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.

H. G. van der Poel, Y. Chen, S. Piantadosi, 2001, Cancer research.

A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.

Hong Zhang, Y. Chen, D. Yu, 2001, Cancer research.

Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.

Hong Zhang, M. Embry, Y. Chen, 2001, Cancer research.

CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity.

T. DeWeese, Y. Chen, D. Karpf, 2001, Cancer research.

An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors

L. Wang, Honglin Li, H. Li, 2009, Cancer Gene Therapy.

The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts.

Y. Chen, D. Yu, D. R. Henderson, 1999, Cancer research.

Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy.

D. Yu, D. R. Henderson, Y. Chen, 2000, Human gene therapy.

Potent and long‐term antiangiogenic efficacy mediated by FP3‐expressing oncolytic adenovirus

C. Yun, J. Yoo, June Kyu Hwang, 2015, International journal of cancer.